This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2005 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was:  Active, not recruiting
CORDA, The Heart Charity
The Cooley’s Anemia Foundation,
Apotex Inc.
The UK Thalassemia Society
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust Identifier:
First received: February 14, 2005
Last updated: June 23, 2005
Last verified: February 2005
Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients have shortened life expectancy with the most common cause of death being heart failure. This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.

Condition Intervention Phase
Beta-Thalassemia Drug: deferiprone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance

Resource links provided by NLM:

Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Myocardial T2*

Secondary Outcome Measures:
  • Liver T2*
  • LV and RV volumes and function in systole and diastole
  • Brachial artery reactivity
  • B-type natriuretic peptide
  • Patient compliance
  • Adverse events
  • Success of blinding

Estimated Enrollment: 65
Study Start Date: May 2004
Estimated Study Completion Date: June 2005
Detailed Description:

Thalassemia Major (TM) is a hereditary anemia resulting from a single gene defect that results in abnormal red cell production. The survival of affected individuals is dependent upon lifelong blood transfusions. Unfortunately, this causes total body iron overload, and 50% of the patients in the UK are dead by the age of 35. Approximately 70% of these deaths result from heart failure which results as a consequence of cardiac iron toxicity.

A Cardiovascular Magnetic Resonance (CMR) technique (which exploits the fact that T2* signal decay relates to tissue iron) developed at the Royal Brompton Hospital provides a non-invasive and reproducible assessment of cardiac iron. CMR therefore provides a very useful method to assess response to new treatments in this condition. Using cardiac T2* as a primary endpoint, we will investigate whether the oral chelator, deferiprone in combination with traditional treatment (deferoxamine), is superior in removing cardiac iron as compared to deferoxamine alone. This trial will provide the first randomized controlled, double-blinded, evidence for the efficacy of combination treatment in TM.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Beta thalassemia major
  • Maintaining pre-transfusion hemoglobin of 9 g/dL
  • Myocardial T2* between 8 and 20 ms
  • Ability to give informed consent
  • Male or female
  • Age >18 years
  • Any ejection fraction
  • Confirmation of effective contraception throughout the trial (both men and women)

Exclusion Criteria:

  • Implant incompatible with MR (magnetic resonance), such as pacemaker, claustrophobia, or other condition making CMR impossible or inadvisable
  • Neutropenia within 12 months (ANC <1.5 x10^9/L), unless normal at screening
  • Thrombocytopenia within 12 months (<50 x10^9/L), unless normal at screening
  • Liver enzymes > 3 times upper limit of normal
  • Patients who have previously received deferiprone for a total of more than 6 months over the last 5 years.
  • Patients with a previous reaction to deferiprone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00103753

Ospedale Microcitemico, Via Jenner
Cagliari, Sardinia, Italy, 09121
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
CORDA, The Heart Charity
The Cooley’s Anemia Foundation,
Apotex Inc.
The UK Thalassemia Society
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00103753     History of Changes
Other Study ID Numbers: 02 065
Study First Received: February 14, 2005
Last Updated: June 23, 2005

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
Randomized Controlled Trial
Iron chelation
Beta Thalassemia Major

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Siderophores processed this record on September 21, 2017